GGTLC1 and metabolic dysfunction-associated steatotic liver disease: Moreover, both ferrostatin‐1 and liproxstatin‐1 repressed HFD‐induced upregulation of serum alanine transaminase, aspartate transaminase, gamma glutamyl transpeptidase, nonalcoholic fatty liver disease activity (NAS) score (Figure S1B), indicating their additional therapeutic potential in nonalcoholic fatty liver disease (NAFLD).